Medical
ATOMIC-Meso Trial: ADI-PEG20 Quadrupled 3-Year Survival Rates in Mesothelioma Breakthrough
David Foster
February 17, 2026
Phase 3 ATOMIC-Meso trial results show pegargiminase (ADI-PEG20) quadrupled 3-year survival rates in mesothelioma. Learn how arginine deprivation therapy works, eligibility, and access to this breakthrough treatment.
11 min read 8 FAQs
Read